Figure 4. a)The CV curves of Zn@CuHCF//V 2 O 5 and bare Zn//V 2 O 5 full cells. b) The charging/discharging curves of Zn@CuHCF//V 2 O 5 cells. c) Rate performance. d) Cycling performance of full cells. e) Ragone plot of Zn@CuHCF//V 2 O 5 cell compared with previously reported AZIBs. [60][61][62][63][64][65][66] f) Schematic diagram of a flexible quasi-solid-state Zn@CuHCF//V 2 O 5 battery. g) The optical images of open circuit voltage of the flexible quasi-solid-state Zn@CuHCF//V 2 O 5 battery in various bending states. h) LED powered by two flexible quasi-solid-state Zn@CuHCF//V 2 O 5 batteries.

No abstract

Epigenetic abnormalities play a vital role in the progression of ovarian cancer. Lysine-specific demethylase 1 (LSD1/KDM1A) acts as an epigenetic regulator and is overexpressed in ovarian tumors. However, the upstream regulator of LSD1 expression in this cancer remains elusive. Here, we show that epidermal growth factor (EGF) signaling upregulates LSD1 protein levels in SKOV3 and HO8910 ovarian cancer cells overexpressing both LSD1 and the EGF receptor. This effect is correlated with a decrease in the dimethylation of H3K4, a major substrate of LSD1, in an LSD1-dependent manner. We also show that inhibition of PI3K/AKT, but not MEK, abolishes the EGF-induced upregulation of LSD1 and cell migration, indicating that the PI3K/PDK1/AKT pathway mediates the EGF-induced expression of LSD1 and cell migration. Significantly, LSD1 knockdown or inhibition of LSD1 activity impairs both intrinsic and EGF-induced cell migration in SKOV3 and HO8910 cells. These results highlight a novel mechanism regulating LSD1 expression and identify LSD1 as a promising therapeutic target for treating metastatic ovarian cancer driven by EGF signaling.

No abstract

No abstract